

November 09, 2021

The Manager (Listing)  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai 400 023

Fax No.2272 5092/3030

Ref. Scrip code: 539680

Sub.: Outcome of Board Meeting held today i.e. November 09, 2021

Dear Sir,

With reference to the captioned subject and in compliance with the regulation 30 and other applicable regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, November 09, 2021 (commenced at 4.30 p.m. and concluded at 5.00 p.m.) inter-alia have considered and approved the un-audited financial results of the Company for the half year ended on September 30, 2021.

A copy of the un-audited Financial Results adopted and approved by the Board of Directors for the half year ended on September 30, 2021 along with limited review report of the Auditors thereon is attached herewith.

Please take the same on your records and suitably disseminated at all concerned.

Thanking you,

Yours faithfully,  
For Ganga Pharmaceuticals Limited



  
Bharat Sharma  
Managing Director  
DIN: 00077026  
Email ID: bharat.sharma@gangapharma.in

Encl.: As above



# Anil Bansal & Associates

— CHARTERED ACCOUNTANTS —

## INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE HALF YEAR ENDED 30.09.2021 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To  
The Board of Director  
Ganga Pharmaceuticals Ltd

We have reviewed the accompanying statement of unaudited financial results of **Ganga Pharmaceuticals Ltd** for the period ended on 30th September, 2021. This Statement is the responsibility of the Company's Management and has been approved by the Board of Director. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (RE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any materials misstatement.


For: Anil Bansal & Associates  
Chartered Accountants  
Firm Registration No. 100421W

Anil Bansal  
Partner

Membership Number 043918  
UDIN: 21043918AAAAFR3685

Place- Mumbai

Date- 09th November, 2021





**GANGA PHARMACEUTICALS LTD**  
CIN: L99999MH1989PLC053392

Registered Office: Gangatol, Dhanvantari Marg, Gopcharpada, Virar (East), Palghar -401305  
Tele Nos.:0250-6098333/444; Website: www.ayurvedganga.com; Email: id.gangapharmaltd@gmail.com

**Statement of Audited Consolidated Assets and Liabilities as at 30th September 2021**

		Rs.in Lacs	
	Statement of Assets and Liabilities Particulars	As at (30-09-2021)	As at (31-03-2021)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
	(1) Shareholders Funds:		
	(a) Share Capital	406.15	406.15
	(b) Reserve & Surplus	131.62	131.14
	(2) Non-Current Liabilities:		
	(a) Long-Term Borrowings	77.17	67.40
	(b) Deferred Tax Liabilities (Net)	0.48	0.72
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	(3) Current Liabilities:		
	(a) Short-term borrowings	108.68	88.47
	(b) Trade payables		
	i) Total outstanding dues of micro enterprises and small enterprises	7.01	1.70
	ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	39.21	42.35
	(c) Other current liabilities	11.33	27.27
	(d) Short-term provisions	1.23	0.83
	<b>Total</b>	<b>782.89</b>	<b>766.03</b>
<b>B</b>	<b>ASSETS</b>		
	(1) Non - Current assets:		
	(a) Fixed Assets	69.50	72.09
	(b) Non-current investments	8.88	8.93
	(c) Deferred tax assets (net)	-	-
	(d) Long term loans and advances	-	-
	(e) Other Non-current assets	229.10	226.23
	(2) Current assets:		
	(a) Current Investment	-	-
	(b) Inventories	114.38	113.29
	(c) Trade receivables	93.01	81.97
	(d) Cash and cash equivalents	1.92	1.45
	(e) Short-term loans and advances	147.11	146.43
	(f) Other current assets	118.99	115.65
	<b>Total</b>	<b>782.89</b>	<b>766.03</b>

For and on behalf of the Board of Directors  
Ganga Pharmaceuticals Limited

Bharat Sharma  
Managing Director  
DIN : 00077026



Place: Virar, Palghar  
Date: 09 November, 2021

## GANGA PHARMACEUTICALS LIMITED

CIN: L99999MH1989PLC053392

REGISTERED OFFICE ADDRESS : GANGATAT, DHANVANTARI MARG, GOPCHAR PADA, VIRAR (EAST)-401305

Tele No. +91-250-6098444 Email id: gangapharma1td@gmail.com , Website: www.ayurvedganga.com

## Statement of Audited Consolidated Financial Results for the Half and Year ended 30 September, 2021.

Sr. No	Particulars	Figures for the half year ended on			Rs. in Lacs	
					Financial year ended on	Financial year ended on
		30-09-2021	31-03-2021	30-09-2020	31-03-2021	31-03-2020
	(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	(Audited)	
1	<b>INCOME FROM OPERATIONS</b>					
	(a) Revenue from operations	124.51	122.96	114.48	237.44	307.88
	(b) Other Income	10.55	18.70	6.73	25.43	16.51
	<b>Total Income</b>	<b>135.06</b>	<b>141.66</b>	<b>121.21</b>	<b>262.86</b>	<b>324.39</b>
2	<b>Expenses</b>					
	(a) Cost of Materials consumed	49.04	94.57	47.57	142.14	116.66
	(b) Purchase of stock in trade					
	(c) Change in inventories of finished goods & packing Material	9.74	(26.42)	7.94	(18.48)	11.05
	(d) Employee Benefit Expenses	25.12	16.79	26.02	42.81	43.63
	(e) Finance Cost	10.11	9.95	9.47	19.42	24.23
	(f) Depreciation and Amortization Expense	2.72	2.69	2.68	5.37	5.42
	(g) Other Administrative Expenses	37.69	42.52	25.35	67.86	97.89
	<b>Total Expenses</b>	<b>134.41</b>	<b>140.10</b>	<b>119.03</b>	<b>259.12</b>	<b>298.89</b>
3	Profit/(Loss) before Tax (3-2)	0.65	1.56	2.18	3.74	25.51
4	Tax Expenses					
	(a) Current Tax	0.41	0.26	0.57	0.83	6.32
	(b) Deferred Tax	(0.24)	0.18	-0.04	0.14	0.31
	(c) Earlier tax	-	0.73	-	0.73	-
5	Net Profit / (Loss) for the period (3-4)	0.48	0.39	1.65	2.04	18.88
6	Other Comprehensive Income				-	-
7	Paid - Up equity share capital ( Equity Share of Rs. 10/- each)	406.15	406.15	406.15	406.15	406.15
8	Earning per equity share (Rs.)					
	(1) Basic	0.01	0.01	0.04	0.05	0.46
	(2) Diluted	0.01	0.01	0.04	0.05	0.46

## Note

- The above results for the half year ended 30-09-2021 have been reviewed by the Audit Committee in their meeting held on 09th November 2021 and approved by the Board of Directors in their meeting held on 09th November 2021.
- By mid of March 2020, novel corona virus (Covid-19) had spread across the world and since then the pandemic has severely affected public health and disrupted economic activities. In response to this pandemic, Governments across the world had to impose various restrictions including lockdowns and mandatory work from home requirements. This has affected the operations of the Company and has had impact on the sales and profitability amongst others. The Company is continuously monitoring the situation and taking necessary actions in response to the developments to minimise the impact and also to safeguard the assets and employees.
- Previous period's figures have been regrouped/reclassified wherever necessary.

For and on behalf of the Board of Directors

Ganga Pharmaceuticals Limited

Bharat Sharma

Managing Director

DIN : 00077026

Place: Virar, Palghar

Date : 09 November, 2021



**GANGA PHARMACEUTICALS LIMITED**

**Cash Flow Statement for the period Ended 30 Septmeber 2021**

	For the Half year ended 30th September Rupees	For the Half year ended 30th September Rupees	For the year ended 31st March 2021 Rupees	(Rs.in Lacs) For the year ended 31st March 2021 Rupees
<b>A. Cash flow from operating activities:</b>				
Net profit before tax as per Profit and Loss Account.		0.65		3.74
Adjustment to reconcile profit before tax to net cash flows :				
Depreciation and amortisation expense	2.72		5.37	
Interest on advance & deposit recd	(10.55)		(25.31)	
Finance cost	10.11		17.91	
Prior period Item	-		-	
		<u>2.27</u>		<u>(2.03)</u>
Operating profit before working capital changes		2.92		1.71
<b>Movements in working capital:</b>				
(Decrease) / Increase in trade payables	2.18		(11.61)	
(Decrease) / Increase in other liabilities	(15.94)		7.45	
(Decrease) / Increase in Short term	20.21		2.56	
(Increase) / Decrease in trade receivables	(11.04)		25.08	
(Increase) / Decrease in other current assets	(3.34)		(8.84)	
(Increase) / Decrease in Short-term loans and advances	(0.68)		(23.63)	
(Increase) / Decrease in Inventories	(1.09)		(9.33)	
		<u>(9.71)</u>		<u>(18.31)</u>
Cash generated from operations		(6.79)		(16.60)
Taxes paid				(0.95)
Net cash from operating activities		<u>(6.79)</u>		<u>(17.55)</u>
<b>B. Cash flow from investing activities:</b>				
Purchase of fixed assets	(0.13)		(1.68)	
Advances given	-		-	
Deposit made / matured during the year	(2.83)		3.99	
Investment made during the year	-		-	
Interest received	10.55		25.31	
Net cash used in investing activities		<u>7.60</u>		<u>27.62</u>



**GANGA PHARMACEUTICALS LIMITED**

**Cash Flow Statement (Contd.)**

	For the Half year ended	For the Half year ended	For the year ended	For the year ended
	31st March 2021	31st March 2021	31st March 2021	31st March 2021
	Rupees	Rupees	Rupees	Rupees
C. Cash flow from financing activities:				
Repayment / proceeds of borrowings	9.77		8.12	
Finance cost	(10.11)		(17.91)	
Net cash used in financing activities		(0.34)		(9.79)
Net increase / (Decrease) in cash and cash equivalents		0.47		0.28
Cash and cash equivalents as at the beginning of the year		1.45		1.17
Cash and cash equivalents as at the end of the year		1.92		1.45
Cash and cash equivalent comprises of :				
Cash in hand		1.70		1.17
Balance with banks		0.23		0.28
Total		1.92		1.45

**Notes:**

- 1 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Notified Accounting Standard - 3 on Cash Flow Statements.
- 2 Figures in bracket indicate cash outgo.
- 3 Previous years' figures have been regrouped/rearranged to conform with current years' classifications.

As per our report of even date

For and on behalf of the Board of Directors of  
Ganga Pharmaceuticals Limited

Bharat Sharma  
Managing Director  
DIN : 00077026



Place : Mumbai

Date: 09th November 2021